Diabetic nephropathy Market By Drugs Class (Angiotensin-converting Enzyme Inhibitors, Angiotensin Receptor Blockers, Calcium Channel Blocker, Diuretics, Renin Inhibitor, Others), By Type (Type-1 Diabetes, Type-2 Diabetes), By Distribution Channel (Hospital Pharmacy, Online Providers, Drug Stores and Retail Pharmacy): Global Opportunity Analysis and Industry Forecast, 2022-2031
Diabetic nephropathy, also known as diabetic kidney disease, is the chronic loss of kidney function occurring in people with diabetes mellitus. Diabetic nephropathy is the leading causes of chronic kidney disease (CKD) and end-stage renal disease (ESRD), globally. Diabetic nephropathy is also defined by elevated urine albumin excretion or reduced glomerular filtration rate (GFR), or both. It is a serious complication that occurs in 20–40% of all diabetic patients.
Diabetic nephropathy is usually diagnosed during routine testing, which is a part of the diabetes management. Routine test used for diagnosis of diabetic nephropathy include urinary albumin test, albumin/creatinine ratio, and glomerular filtration rate (GFR) and other special tests such as imaging tests (CT scanning, MRI) and Kidney biopsy.
Treatments of diabetic nephropathy are very necessary for patients. The first step in treating diabetic nephropathy is to treat and control diabetes and high blood pressure (hypertension). This includes diet, lifestyle changes, exercise, prescription medications, blood pressure control medicine, blood sugar control medicine, G-Protein Coupled Receptors (GPCR), and antioxidant inflammation modulators medicine. Furthermore, kidney dialysis, transplant, and symptom management treatment are also used for advanced diabetic kidney diseases. The diabetic nephropathy market is growing at rapid rate. Major factors driving growth of the diabetic nephropathy market include increase in geriatric population suffering from diabetes, increase in diabetic population, and rise in incidences of various kidney diseases. For instance, according to the Journal of Nutrition and Metabolism, in a survey at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia, the incidence rate of diabetic nephropathy was 14 (95% CI 10.8–17.7) cases per 10,000 patients. In addition, 63 (13.6%) diabetes mellitus (DM) patients developed diabetic nephropathy. Type 2 DM patients who had coronary heart diseases and anemia were at higher hazard of developing diabetic nephropathy. Hence, such factors propel the market growth.
For instance, according to the National Diabetes Statistics Latest Report, 37.3 million people had diabetes (11.3% of the US population) in which 28.7 million people, including 28.5 million adults were diagnosed and 8.5 million people (23.0% of adults are undiagnosed) were undiagnosed in the U.S from 2017 to 2020.
Moreover, surge in diabetes and chronic kidney diseases leads to increase in number of diabetic nephropathies, which further require anti-diabetic nephropathy medicines, thus propelling adoption of anti-diabetic nephropathy medicine. Angiotensin-converting enzyme inhibitors have become more popular among products of diabetic nephropathy. Type-2 diabetes is the most trending diabetic nephropathy that draws attention of customers, fueling growth of the diabetic nephropathy market. In addition, technological advancements; launch of various products; strategies among key players such as acquisition, collaboration, and agreement drive the diabetic nephropathy market. For instance, AstraZeneca Plc. got approval in Japan and Europe for Forxiga as its key developmental strategy to sustain the intense competition and improve its product portfolio.
However, unfavorable reimbursements as well as complications such as the market growth is limited by stricter regulatory standards and lengthy drug approval times. The market growth of the diabetic nephropathy is also restrained, owing to lack of comprehensive therapeutic therapy for diabetic nephropathy.
Furthermore, healthcare business is predicted to witness growth, owing to rise in prevalence of diabetes and obesity, increase in R&D investments in drug discovery & development, and rise in awareness regarding diabetes and kidney-related disorders. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.
The diabetic nephropathy market is segmented on the basis of drug class, type, distribution channel, and region. On the basis of drug class, the market is classified into angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blocker, diuretics, renin inhibitor, and others. By type, the market is segregated into type-1 diabetes and type-2 diabetes. Depending on distribution channel, it is fragmented into hospital pharmacy, online providers, and drug stores & retail pharmacy. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA)
Major players profiled in the report are Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bayer Ag, Eli Lilly and Company, Merck & Co, Inc., Novartis Ag, Pfizer Inc., Reata Pharmaceuticals, Inc., and Sanofi.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the diabetic nephropathy market analysis from 2021 to 2031 to identify the prevailing diabetic nephropathy market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the diabetic nephropathy market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global diabetic nephropathy market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Distribution Channel
Hospital Pharmacy
Online Providers
Drug Stores and Retail Pharmacy
By Drugs Class
Angiotensin-converting Enzyme Inhibitors
Angiotensin Receptor Blockers
Calcium Channel Blocker
Diuretics
Renin Inhibitor
Others
By Type
Type-1 Diabetes
Type-2 Diabetes
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Bayer AG
Abbott Laboratories
Astrazenica Plc
Eli Lilly and Company
Pfizer Inc.
Sanofi
Novartis AG
Merck & Co
AbbVie Inc.
Reata Pharmaceuticals
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter’s five forces analysis
- 3.3.1. Low bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. Low intensity of rivalry
- 3.3.5. Low bargaining power of buyers
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Surge in number of geriatric populations suffering from diabetes and rise in prevalence of chronic kidney diseases, obesity, and hypertension
- 3.4.1.2. Rise in awareness regarding diabetic nephropathy and increase in diagnostic tests
- 3.4.2. Restraints
- 3.4.2.1. Strict regulatory rules and lengthy drug approval times
- 3.4.3. Opportunities
- 3.4.3.1. Rise in use of combination therapy for diabetic nephropathy
- 3.4.3.2. Increase in R&D investments in drug discovery and development
- 3.5. COVID-19 Impact Analysis on the market
- CHAPTER 4: DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Angiotensin-converting Enzyme Inhibitors
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. Angiotensin Receptor Blockers
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- 4.4. Calcium Channel Blocker
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
- 4.5. Diuretics
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country
- 4.6. Renin Inhibitor
- 4.6.1. Key market trends, growth factors and opportunities
- 4.6.2. Market size and forecast, by region
- 4.6.3. Market share analysis by country
- 4.7. Others
- 4.7.1. Key market trends, growth factors and opportunities
- 4.7.2. Market size and forecast, by region
- 4.7.3. Market share analysis by country
- CHAPTER 5: DIABETIC NEPHROPATHY MARKET, BY TYPE
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Type-1 Diabetes
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. Type-2 Diabetes
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- CHAPTER 6: DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Hospital Pharmacy
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. Online Providers
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- 6.4. Drug Stores and Retail Pharmacy
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
- CHAPTER 7: DIABETIC NEPHROPATHY MARKET, BY REGION
- 7.1. Overview
- 7.1.1. Market size and forecast By Region
- 7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Drugs Class
- 7.2.3. Market size and forecast, by Type
- 7.2.4. Market size and forecast, by Distribution Channel
- 7.2.5. Market size and forecast, by country
- 7.2.5.1. U.S.
- 7.2.5.1.1. Key market trends, growth factors and opportunities
- 7.2.5.1.2. Market size and forecast, by Drugs Class
- 7.2.5.1.3. Market size and forecast, by Type
- 7.2.5.1.4. Market size and forecast, by Distribution Channel
- 7.2.5.2. Canada
- 7.2.5.2.1. Key market trends, growth factors and opportunities
- 7.2.5.2.2. Market size and forecast, by Drugs Class
- 7.2.5.2.3. Market size and forecast, by Type
- 7.2.5.2.4. Market size and forecast, by Distribution Channel
- 7.2.5.3. Mexico
- 7.2.5.3.1. Key market trends, growth factors and opportunities
- 7.2.5.3.2. Market size and forecast, by Drugs Class
- 7.2.5.3.3. Market size and forecast, by Type
- 7.2.5.3.4. Market size and forecast, by Distribution Channel
- 7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Drugs Class
- 7.3.3. Market size and forecast, by Type
- 7.3.4. Market size and forecast, by Distribution Channel
- 7.3.5. Market size and forecast, by country
- 7.3.5.1. Germany
- 7.3.5.1.1. Key market trends, growth factors and opportunities
- 7.3.5.1.2. Market size and forecast, by Drugs Class
- 7.3.5.1.3. Market size and forecast, by Type
- 7.3.5.1.4. Market size and forecast, by Distribution Channel
- 7.3.5.2. France
- 7.3.5.2.1. Key market trends, growth factors and opportunities
- 7.3.5.2.2. Market size and forecast, by Drugs Class
- 7.3.5.2.3. Market size and forecast, by Type
- 7.3.5.2.4. Market size and forecast, by Distribution Channel
- 7.3.5.3. U.K.
- 7.3.5.3.1. Key market trends, growth factors and opportunities
- 7.3.5.3.2. Market size and forecast, by Drugs Class
- 7.3.5.3.3. Market size and forecast, by Type
- 7.3.5.3.4. Market size and forecast, by Distribution Channel
- 7.3.5.4. Italy
- 7.3.5.4.1. Key market trends, growth factors and opportunities
- 7.3.5.4.2. Market size and forecast, by Drugs Class
- 7.3.5.4.3. Market size and forecast, by Type
- 7.3.5.4.4. Market size and forecast, by Distribution Channel
- 7.3.5.5. Spain
- 7.3.5.5.1. Key market trends, growth factors and opportunities
- 7.3.5.5.2. Market size and forecast, by Drugs Class
- 7.3.5.5.3. Market size and forecast, by Type
- 7.3.5.5.4. Market size and forecast, by Distribution Channel
- 7.3.5.6. Rest of Europe
- 7.3.5.6.1. Key market trends, growth factors and opportunities
- 7.3.5.6.2. Market size and forecast, by Drugs Class
- 7.3.5.6.3. Market size and forecast, by Type
- 7.3.5.6.4. Market size and forecast, by Distribution Channel
- 7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Drugs Class
- 7.4.3. Market size and forecast, by Type
- 7.4.4. Market size and forecast, by Distribution Channel
- 7.4.5. Market size and forecast, by country
- 7.4.5.1. Japan
- 7.4.5.1.1. Key market trends, growth factors and opportunities
- 7.4.5.1.2. Market size and forecast, by Drugs Class
- 7.4.5.1.3. Market size and forecast, by Type
- 7.4.5.1.4. Market size and forecast, by Distribution Channel
- 7.4.5.2. China
- 7.4.5.2.1. Key market trends, growth factors and opportunities
- 7.4.5.2.2. Market size and forecast, by Drugs Class
- 7.4.5.2.3. Market size and forecast, by Type
- 7.4.5.2.4. Market size and forecast, by Distribution Channel
- 7.4.5.3. Australia
- 7.4.5.3.1. Key market trends, growth factors and opportunities
- 7.4.5.3.2. Market size and forecast, by Drugs Class
- 7.4.5.3.3. Market size and forecast, by Type
- 7.4.5.3.4. Market size and forecast, by Distribution Channel
- 7.4.5.4. India
- 7.4.5.4.1. Key market trends, growth factors and opportunities
- 7.4.5.4.2. Market size and forecast, by Drugs Class
- 7.4.5.4.3. Market size and forecast, by Type
- 7.4.5.4.4. Market size and forecast, by Distribution Channel
- 7.4.5.5. South Korea
- 7.4.5.5.1. Key market trends, growth factors and opportunities
- 7.4.5.5.2. Market size and forecast, by Drugs Class
- 7.4.5.5.3. Market size and forecast, by Type
- 7.4.5.5.4. Market size and forecast, by Distribution Channel
- 7.4.5.6. Rest of Asia-Pacific
- 7.4.5.6.1. Key market trends, growth factors and opportunities
- 7.4.5.6.2. Market size and forecast, by Drugs Class
- 7.4.5.6.3. Market size and forecast, by Type
- 7.4.5.6.4. Market size and forecast, by Distribution Channel
- 7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Drugs Class
- 7.5.3. Market size and forecast, by Type
- 7.5.4. Market size and forecast, by Distribution Channel
- 7.5.5. Market size and forecast, by country
- 7.5.5.1. Brazil
- 7.5.5.1.1. Key market trends, growth factors and opportunities
- 7.5.5.1.2. Market size and forecast, by Drugs Class
- 7.5.5.1.3. Market size and forecast, by Type
- 7.5.5.1.4. Market size and forecast, by Distribution Channel
- 7.5.5.2. Saudi Arabia
- 7.5.5.2.1. Key market trends, growth factors and opportunities
- 7.5.5.2.2. Market size and forecast, by Drugs Class
- 7.5.5.2.3. Market size and forecast, by Type
- 7.5.5.2.4. Market size and forecast, by Distribution Channel
- 7.5.5.3. South Africa
- 7.5.5.3.1. Key market trends, growth factors and opportunities
- 7.5.5.3.2. Market size and forecast, by Drugs Class
- 7.5.5.3.3. Market size and forecast, by Type
- 7.5.5.3.4. Market size and forecast, by Distribution Channel
- 7.5.5.4. Rest of LAMEA
- 7.5.5.4.1. Key market trends, growth factors and opportunities
- 7.5.5.4.2. Market size and forecast, by Drugs Class
- 7.5.5.4.3. Market size and forecast, by Type
- 7.5.5.4.4. Market size and forecast, by Distribution Channel
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top player positioning, 2021
- CHAPTER 9: COMPANY PROFILES
- 9.1. AbbVie Inc.
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.2. Abbott Laboratories
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.3. Bayer AG
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.4. Eli Lilly and Company
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.5. Merck & Co
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.6. Astrazenica Plc
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.7. Novartis AG
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.8. Pfizer Inc.
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.9. Reata Pharmaceuticals
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.10. Sanofi
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- LIST OF TABLES
- TABLE 01. GLOBAL DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
- TABLE 02. DIABETIC NEPHROPATHY MARKET FOR ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, BY REGION, 2021-2031 ($MILLION)
- TABLE 03. DIABETIC NEPHROPATHY MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 04. DIABETIC NEPHROPATHY MARKET FOR CALCIUM CHANNEL BLOCKER, BY REGION, 2021-2031 ($MILLION)
- TABLE 05. DIABETIC NEPHROPATHY MARKET FOR DIURETICS, BY REGION, 2021-2031 ($MILLION)
- TABLE 06. DIABETIC NEPHROPATHY MARKET FOR RENIN INHIBITOR, BY REGION, 2021-2031 ($MILLION)
- TABLE 07. DIABETIC NEPHROPATHY MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 08. GLOBAL DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 09. DIABETIC NEPHROPATHY MARKET FOR TYPE-1 DIABETES, BY REGION, 2021-2031 ($MILLION)
- TABLE 10. DIABETIC NEPHROPATHY MARKET FOR TYPE-2 DIABETES, BY REGION, 2021-2031 ($MILLION)
- TABLE 11. GLOBAL DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 12. DIABETIC NEPHROPATHY MARKET FOR HOSPITAL PHARMACY, BY REGION, 2021-2031 ($MILLION)
- TABLE 13. DIABETIC NEPHROPATHY MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 14. DIABETIC NEPHROPATHY MARKET FOR DRUG STORES AND RETAIL PHARMACY, BY REGION, 2021-2031 ($MILLION)
- TABLE 15. DIABETIC NEPHROPATHY MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 16. NORTH AMERICA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
- TABLE 17. NORTH AMERICA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 18. NORTH AMERICA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 19. NORTH AMERICA DIABETIC NEPHROPATHY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 20. U.S. DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
- TABLE 21. U.S. DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 22. U.S. DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 23. CANADA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
- TABLE 24. CANADA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 25. CANADA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 26. MEXICO DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
- TABLE 27. MEXICO DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 28. MEXICO DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 29. EUROPE DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
- TABLE 30. EUROPE DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 31. EUROPE DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 32. EUROPE DIABETIC NEPHROPATHY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 33. GERMANY DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
- TABLE 34. GERMANY DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 35. GERMANY DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 36. FRANCE DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
- TABLE 37. FRANCE DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 38. FRANCE DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 39. U.K. DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
- TABLE 40. U.K. DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 41. U.K. DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 42. ITALY DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
- TABLE 43. ITALY DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 44. ITALY DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 45. SPAIN DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
- TABLE 46. SPAIN DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 47. SPAIN DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 48. REST OF EUROPE DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
- TABLE 49. REST OF EUROPE DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 50. REST OF EUROPE DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 51. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
- TABLE 52. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 53. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 54. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 55. JAPAN DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
- TABLE 56. JAPAN DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 57. JAPAN DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 58. CHINA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
- TABLE 59. CHINA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 60. CHINA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 61. AUSTRALIA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
- TABLE 62. AUSTRALIA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 63. AUSTRALIA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 64. INDIA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
- TABLE 65. INDIA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 66. INDIA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 67. SOUTH KOREA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
- TABLE 68. SOUTH KOREA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 69. SOUTH KOREA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 70. REST OF ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
- TABLE 71. REST OF ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 72. REST OF ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 73. LAMEA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
- TABLE 74. LAMEA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 75. LAMEA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 76. LAMEA DIABETIC NEPHROPATHY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 77. BRAZIL DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
- TABLE 78. BRAZIL DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 79. BRAZIL DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 80. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
- TABLE 81. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 82. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 83. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
- TABLE 84. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 85. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 86. REST OF LAMEA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
- TABLE 87. REST OF LAMEA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 88. REST OF LAMEA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 89. ABBVIE INC.: KEY EXECUTIVES
- TABLE 90. ABBVIE INC.: COMPANY SNAPSHOT
- TABLE 91. ABBVIE INC.: PRODUCT SEGMENTS
- TABLE 92. ABBVIE INC.: PRODUCT PORTFOLIO
- TABLE 93. ABBOTT LABORATORIES: KEY EXECUTIVES
- TABLE 94. ABBOTT LABORATORIES: COMPANY SNAPSHOT
- TABLE 95. ABBOTT LABORATORIES: PRODUCT SEGMENTS
- TABLE 96. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
- TABLE 97. BAYER AG: KEY EXECUTIVES
- TABLE 98. BAYER AG: COMPANY SNAPSHOT
- TABLE 99. BAYER AG: PRODUCT SEGMENTS
- TABLE 100. BAYER AG: PRODUCT PORTFOLIO
- TABLE 101. ELI LILLY AND COMPANY: KEY EXECUTIVES
- TABLE 102. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
- TABLE 103. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
- TABLE 104. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
- TABLE 105. MERCK & CO: KEY EXECUTIVES
- TABLE 106. MERCK & CO: COMPANY SNAPSHOT
- TABLE 107. MERCK & CO: PRODUCT SEGMENTS
- TABLE 108. MERCK & CO: PRODUCT PORTFOLIO
- TABLE 109. ASTRAZENICA PLC: KEY EXECUTIVES
- TABLE 110. ASTRAZENICA PLC: COMPANY SNAPSHOT
- TABLE 111. ASTRAZENICA PLC: PRODUCT SEGMENTS
- TABLE 112. ASTRAZENICA PLC: PRODUCT PORTFOLIO
- TABLE 113. NOVARTIS AG: KEY EXECUTIVES
- TABLE 114. NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 115. NOVARTIS AG: PRODUCT SEGMENTS
- TABLE 116. NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 117. PFIZER INC.: KEY EXECUTIVES
- TABLE 118. PFIZER INC.: COMPANY SNAPSHOT
- TABLE 119. PFIZER INC.: PRODUCT SEGMENTS
- TABLE 120. PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 121. REATA PHARMACEUTICALS: KEY EXECUTIVES
- TABLE 122. REATA PHARMACEUTICALS: COMPANY SNAPSHOT
- TABLE 123. REATA PHARMACEUTICALS: SERVICE SEGMENTS
- TABLE 124. REATA PHARMACEUTICALS: PRODUCT PORTFOLIO
- TABLE 125. SANOFI: KEY EXECUTIVES
- TABLE 126. SANOFI: COMPANY SNAPSHOT
- TABLE 127. SANOFI: PRODUCT SEGMENTS
- TABLE 128. SANOFI: PRODUCT PORTFOLIO
- LIST OF FIGURES
- FIGURE 01. DIABETIC NEPHROPATHY MARKET, 2021-2031
- FIGURE 02. SEGMENTATION OF DIABETIC NEPHROPATHY MARKET,2021-2031
- FIGURE 03. TOP INVESTMENT POCKETS IN DIABETIC NEPHROPATHY MARKET (2022-2031)
- FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
- FIGURE 05. LOW THREAT OF NEW ENTRANTS
- FIGURE 06. LOW THREAT OF SUBSTITUTES
- FIGURE 07. LOW INTENSITY OF RIVALRY
- FIGURE 08. LOW BARGAINING POWER OF BUYERS
- FIGURE 09. GLOBAL DIABETIC NEPHROPATHY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 10. DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021(%)
- FIGURE 11. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, BY COUNTRY 2021 AND 2031(%)
- FIGURE 12. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS, BY COUNTRY 2021 AND 2031(%)
- FIGURE 13. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR CALCIUM CHANNEL BLOCKER, BY COUNTRY 2021 AND 2031(%)
- FIGURE 14. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR DIURETICS, BY COUNTRY 2021 AND 2031(%)
- FIGURE 15. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR RENIN INHIBITOR, BY COUNTRY 2021 AND 2031(%)
- FIGURE 16. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)
- FIGURE 17. DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021(%)
- FIGURE 18. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR TYPE-1 DIABETES, BY COUNTRY 2021 AND 2031(%)
- FIGURE 19. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR TYPE-2 DIABETES, BY COUNTRY 2021 AND 2031(%)
- FIGURE 20. DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
- FIGURE 21. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR HOSPITAL PHARMACY, BY COUNTRY 2021 AND 2031(%)
- FIGURE 22. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021 AND 2031(%)
- FIGURE 23. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR DRUG STORES AND RETAIL PHARMACY, BY COUNTRY 2021 AND 2031(%)
- FIGURE 24. DIABETIC NEPHROPATHY MARKET BY REGION, 2021(%)
- FIGURE 25. U.S. DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
- FIGURE 26. CANADA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
- FIGURE 27. MEXICO DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
- FIGURE 28. GERMANY DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
- FIGURE 29. FRANCE DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
- FIGURE 30. U.K. DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
- FIGURE 31. ITALY DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
- FIGURE 32. SPAIN DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
- FIGURE 33. REST OF EUROPE DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
- FIGURE 34. JAPAN DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
- FIGURE 35. CHINA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
- FIGURE 36. AUSTRALIA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
- FIGURE 37. INDIA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
- FIGURE 38. SOUTH KOREA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
- FIGURE 39. REST OF ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
- FIGURE 40. BRAZIL DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
- FIGURE 41. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
- FIGURE 42. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
- FIGURE 43. REST OF LAMEA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
- FIGURE 44. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 45. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 46. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 47. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 48. COMPETITIVE DASHBOARD
- FIGURE 49. COMPETITIVE HEATMAP: DIABETIC NEPHROPATHY MARKET
- FIGURE 50. TOP PLAYER POSITIONING, 2021
- FIGURE 51. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 52. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 53. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 54. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
- FIGURE 55. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 56. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 57. BAYER AG: NET SALES, 2020-2022 ($MILLION)
- FIGURE 58. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 59. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 60. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
- FIGURE 61. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 62. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 63. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 64. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 65. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 66. REATA PHARMACEUTICALS: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
- FIGURE 67. REATA PHARMACEUTICALS: NET REVENUE, 2020-2022 ($MILLION)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook